# US 2010/0166673 A1 · Aerosolized fluoroquinolones and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166673 A1
- Document ID: US20100166673A1
- Status: Published application
- Kind: A1
- Application number: 12/604,340
- Filed: 2009-10-22
- Published: 2010-07-01
- Earliest claimed: 2005-05-18
- Assignees: Mpex Pharmaceuticals, Inc.
- Inventors: Mark W. Surber; Keith A. Bostian; Michael N. Dudley; Olga Lomovskaya; David C. Griffith
- Web page: https://patentgrep.com/patent/US20100166673A1

## CPC

- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/02: Inorganic compounds
- A61P 31/04: Antibacterial agents
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

## Claims

### Claim 1

A method of treating a lung infection, comprising administering an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to a lung.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lung infection is caused by one or more of the following bacteria: Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholera, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Burkholderia cepacia, Francisella tularensis, Kingella, and Moraxella.

### Claim 3 (depends on 1)

The method of claim 1, wherein the lung infection is caused by one or more of the following bacteria: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Haemophilus influenzae, Burkholderia cepacia, and Moraxella.

### Claim 4 (depends on 1)

The method of claim 1, wherein the lung infection is caused by a Burkholderia bacteria.

### Claim 5 (depends on 1)

The method of claim 1, wherein the lung infection is pneumonia.

### Claim 6 (depends on 1)

The method of claim 1, wherein the lung infection is caused by a gram-negative anaerobic bacteria.

### Claim 7 (depends on 1)

The method of claim 1, wherein the lung infection is caused by one or more of the bacteria selected from the group consisting of Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, and Bacteroides splanchnicus.

### Claim 8 (depends on 1)

The method of claim 1, wherein the lung infection is caused by a gram-positive bacteria.

### Claim 9 (depends on 1)

The method of claim 1, wherein the lung infection is caused by one or more of the bacteria selected from the group consisting of Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus milleri; Streptococcus (Group G); Streptococcus (Group C/F); Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus.

### Claim 10 (depends on 1)

The method of claim 1, wherein the lung infection is caused by a gram-positive anaerobic bacteria.

### Claim 11 (depends on 1)

The method of claim 1, wherein the lung infection is caused by one or more bacteria selected from the group consisting of Clostridium difficile, Clostridium perfringens, Clostridium tetini, and Clostridium botulinum.

### Claim 12 (depends on 1)

The method of claim 1, wherein the lung infection is caused by an acid-fast bacteria.

### Claim 13 (depends on 1)

The method of claim 1, wherein the lung infection is caused by a Mycobacterium bacteria.

### Claim 14 (depends on 13)

The method of claim 13, wherein the lung infection is caused by one or more bacteria selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium leprae.

### Claim 15 (depends on 1)

The method of claim 1, wherein the lung infection is caused by an atypical bacteria.

### Claim 16 (depends on 1)

The method of claim 1, wherein the lung infection is caused by one or more bacteria selected from the group consisting of Chlamydia pneumoniae and Mycoplasma pneumoniae.

### Claim 17 (depends on 1)

The method of claim 1, wherein the solution comprises levofloxacin at a concentration from about 100 mM to about 625 mM and magnesium chloride at a concentration from about 125 mM to about 250 mM, has a pH from about 5.5 to about 6.5, and an osmolality from about 350 mOsmol/kg to about 750 mOsmol/kg.

### Claim 18 (depends on 1)

The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns.

### Claim 19 (depends on 1)

The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns.

### Claim 20 (depends on 1)

The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns.

### Claim 21 (depends on 1)

The method of claim 1, comprising producing the aerosol with a vibrating mesh nebulizer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the vibrating mesh nebulizer is a PART E-FLOW® nebulizer.

### Claim 23 (depends on 21)

The method of claim 21, wherein the aerosol comprises a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns.

### Claim 24 (depends on 21)

The method of claim 21, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns.

### Claim 25 (depends on 21)

The method of claim 21, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns.

### Claim 26 (depends on 1)

The method of claim 1, wherein at least about 20 mg of levofloxacin or ofloxacin is administered to the lung.

### Claim 27 (depends on 1)

The method of claim 1, wherein at least about 100 mg of levofloxacin or ofloxacin is administered to the lung.

### Claim 28 (depends on 1)

The method of claim 1, wherein at least about 125 mg of levofloxacin or ofloxacin is administered to the lung.

### Claim 29 (depends on 1)

The method of claim 1, wherein at least about 150 mg of levofloxacin or ofloxacin is administered to the lung.

### Claim 30 (depends on 1)

The method of claim 1, wherein the aerosol is administered to the lung in less than about 10 minutes.

### Claim 31 (depends on 1)

The method of claim 1, wherein the aerosol is administered to the lung in less than about 5 minutes.

### Claim 32 (depends on 1)

The method of claim 1, wherein the aerosol is administered to the lung in less than about 3 minutes.

### Claim 33 (depends on 1)

The method of claim 1, wherein the aerosol is administered to the lung in less than about 2 minutes.

### Claim 34 (depends on 1)

The method of claim 1, further comprising the step of alternating the administration of said aerosol with administration of a second inhaled antimicrobial.

### Claim 35 (depends on 34)

The method of claim 34, wherein the second inhaled antimicrobial is an aminoglycoside.

### Claim 36 (depends on 35)

The method of claim 35, wherein the aminoglycoside is tobramycin.

### Claim 37 (depends on 34)

The method of claim 34, wherein the second inhaled antimicrobial is a polymyxin.

### Claim 38 (depends on 37)

The method of claim 37, wherein the polymyxin is colistin.

### Claim 39 (depends on 34)

The method of claim 34, wherein the second inhaled antimicrobial is a monobactam.

### Claim 40 (depends on 39)

The method of claim 39, wherein the monobactam is aztreonam.

### Claim 41 (depends on 1)

The method of claim 1, comprising administering the aerosol once daily.

### Claim 42 (depends on 1)

The method of claim 1, comprising administering the aerosol twice daily.
